首页> 美国卫生研究院文献>Theranostics >Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
【2h】

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

机译:小ber碱在心血管和代谢性疾病中的作用:从机理到治疗方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
机译:心血管和代谢性疾病(CVMD)是全球范围内的主要死亡原因,突显了开发新药物疗法的迫切需要。小ber碱(BBR)是中草药和印度草药的重要组成部分,已有2000多年的历史。最近,BBR在治疗和/或管理CVMD方面的药理作用引起了人们的极大兴趣。基础,转化和临床研究的最新发现已经确定了BBR的许多新型分子靶标(例如AMPK,SIRT1,LDLR,PCSK9和PTP1B),并提供了支持BBR对抗CVMD的潜在治疗潜力的新证据。因此,本综述提供了BBR在CVMD中的药理特性和治疗应用的及时概述,并强调了最近的药理学进展,这些进展证实了BBR是抗CVMD的有前途的先导药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号